Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17621270
Preet A, Ganju RK, Groopman JE (2008) Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27, 339-46 17621270
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), SW-1573 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
dronabinol no change compared to control
dronabinol EGF inhibit treatment-induced increase
EGF increase
dronabinol no change compared to control
dronabinol EGF inhibit treatment-induced increase
dronabinol decrease

Y1197-p - EGFR (human)
Modsite: stAENAEyLRVAPQS SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y1197‑p, EGFR iso2 (human): , EGFR iso5 (human): , EGFR (mouse): Y1197‑p, EGFR (rat): Y1196‑p, EGFR (pig): Y1196‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), SW-1573 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
dronabinol EGF no effect upon treatment-induced increase
dronabinol no change compared to control

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), SW-1573 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
dronabinol decrease
dronabinol EGF inhibit treatment-induced increase
EGF increase
dronabinol no change compared to control
dronabinol EGF no effect upon treatment-induced increase
dronabinol decrease
EGF increase
dronabinol decrease
dronabinol EGF inhibit treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), SW-1573 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dronabinol decrease
EGF increase
dronabinol no change compared to control
dronabinol EGF no effect upon treatment-induced increase
EGF increase
dronabinol decrease
dronabinol EGF inhibit treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), SW-1573 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dronabinol decrease
EGF increase
dronabinol no change compared to control
dronabinol EGF no effect upon treatment-induced increase
EGF increase
dronabinol decrease
dronabinol EGF inhibit treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), SW-1573 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dronabinol decrease
EGF increase
dronabinol no change compared to control
dronabinol EGF no effect upon treatment-induced increase
EGF increase
dronabinol decrease
dronabinol EGF inhibit treatment-induced increase

Y397-p - FAK (human)
Modsite: sVsEtDDyAEIIDEE SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y397‑p, FAK iso2 (human): Y216‑p, FAK iso5 (human): Y397‑p, FAK (mouse): Y397‑p, FAK iso2 (mouse): Y428‑p, FAK iso4 (mouse): Y397‑p, FAK iso9 (mouse): , FAK (rat): Y397‑p, FAK (chicken): Y397‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), SW-1573 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
dronabinol EGF augment treatment-induced increase
dronabinol increase
dronabinol decrease

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), SW-1573 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
dronabinol no change compared to control
dronabinol EGF inhibit treatment-induced increase
EGF increase
dronabinol no change compared to control
dronabinol EGF no effect upon treatment-induced increase

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), SW-1573 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
dronabinol no change compared to control
dronabinol EGF inhibit treatment-induced increase
EGF increase
dronabinol no change compared to control
dronabinol EGF no effect upon treatment-induced increase

T183-p - JNK2 (human)
Modsite: ACtNFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), SW-1573 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
dronabinol no change compared to control
dronabinol EGF inhibit treatment-induced increase
EGF increase
dronabinol no change compared to control
dronabinol EGF no effect upon treatment-induced increase

Y185-p - JNK2 (human)
Modsite: tNFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), SW-1573 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
dronabinol no change compared to control
dronabinol EGF inhibit treatment-induced increase
EGF increase
dronabinol no change compared to control
dronabinol EGF no effect upon treatment-induced increase